百利天恒收到 2.5 亿美元里程金

Core Insights - SystImmune, a subsidiary of BaiLi Tianheng, has received a milestone payment of $250 million from BMS due to the achievement of a key clinical trial milestone for the IZABRIGHT-Breast01 trial [1][2] Group 1: Financial Details - The milestone payment of $250 million is part of a collaboration agreement with BMS, which includes potential future payments of up to $250 million and additional payments of up to $7.1 billion upon reaching specific development, registration, and sales milestones [2][3] - The total collaboration agreement with BMS for the EGFR/HER3 dual antibody ADC product Iza-bren amounts to $8.4 billion, including an upfront payment of $800 million [2][3] Group 2: Product Development - Iza-bren is currently under development for indications including nasopharyngeal carcinoma in China and is also undergoing Phase II/III clinical trials for non-small cell lung cancer, breast cancer, and urothelial carcinoma globally [2][3]